Eesti - eesti - Ravimiamet

sanoswiss uab - metformiin+vildagliptiin - õhukese polümeerikattega tablett - 850mg+50mg 60tk; 850mg+50mg 30tk; 850mg+50mg 10tk; 850mg+50mg 56tk; 850mg+50mg 120tk; 850mg+50mg 180tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin, metformiin vesinikkloriid - suhkurtõbi, tüüp 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - eucreas is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.

Euroopa Liit - eesti - EMA (European Medicines Agency)

novartis europharm limited - vildagliptiin - suhkurtõbi, tüüp 2 - diabeetis kasutatavad ravimid - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.

Euroopa Liit - eesti - EMA (European Medicines Agency)

novartis europharm limited - vildagliptiin - suhkurtõbi, tüüp 2 - dipeptidyl peptidase 4 (dpp-4) inhibitors, drugs used in diabetes - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 ja 5. 1 erinevate kombinatsioonide kohta kättesaadavate andmete osas).

Euroopa Liit - eesti - EMA (European Medicines Agency)

novartis europharm limited - vildagliptiin - suhkurtõbi, tüüp 2 - diabeetis kasutatavad ravimid - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 ja 5. 1 erinevate kombinatsioonide kohta kättesaadavate andmete osas).

Eesti - eesti - Ravimiamet

zentiva k.s. - metformiin+vildagliptiin - õhukese polümeerikattega tablett - 1000mg+50mg 30tk; 1000mg+50mg 10tk; 1000mg+50mg 60tk

Eesti - eesti - Ravimiamet

zentiva k.s. - metformiin+vildagliptiin - õhukese polümeerikattega tablett - 850mg+50mg 180tk; 850mg+50mg 10tk; 850mg+50mg 60tk

Eesti - eesti - Ravimiamet

medochemie limited - vildagliptiin - tablett - 50mg 112tk; 50mg 180tk; 50mg 56tk; 50mg 28tk; 50mg 30tk; 50mg 90tk; 50mg 60tk; 50mg 14tk; 50mg 336tk

Eesti - eesti - Ravimiamet

medochemie limited - metformiin+vildagliptiin - õhukese polümeerikattega tablett - 850mg+50mg 60tk; 850mg+50mg 180tk; 850mg+50mg 30tk; 850mg+50mg 10tk

Eesti - eesti - Ravimiamet

sandoz pharmaceuticals d.d. - metformiin+vildagliptiin - õhukese polümeerikattega tablett - 850mg+50mg 30tk